Resminostat

Drug Profile

Resminostat

Alternative Names: 4SC-201; BYK 408740; RAS 2410; YHI-1001

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator Nycomed
  • Developer 4SC; Yakult Honsha
  • Class Antineoplastics; Dimethylamines; Hydroxylamines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Hodgkin's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Biliary cancer; Hepatocellular carcinoma; Hodgkin's disease; Mycosis fungoides; Non-small cell lung cancer; Pancreatic cancer; Sezary syndrome
  • Phase I/II Colorectal cancer
  • Phase I Cutaneous T cell lymphoma; Solid tumours
  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 29 Nov 2016 Preclinical trials in Diffuse large B cell lymphoma in Germany (unspecified route) before November 2016
  • 29 Nov 2016 Pharmacodynamics data from a preclinical study in Diffuse large B cell lymphoma presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 20 Oct 2016 Phase-II clinical trials in Mycosis fungoides (Second-line therapy or greater, Late-stage disease) in Austria (PO) (EudraCT2016-000807-99)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top